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Abstract
Background: Glycated albumin (GA) has been increasingly used as a reliable index for short-term glycemic monitoring, and
is inversely associated with b-cell function. Because the pathophysiologic nature of type 2 diabetes (T2D) is characterized by
progressive decline in insulin secretion, the aim was to determine whether GA levels were affected by diabetes duration in
subjects with T2D.
Methods: To minimize the effect of glucose variability on GA, subjects with stably maintained HbA1c levels of ,0.5%
fluctuation across 6 months of measurements were included. Patients with newly diagnosed T2D (n= 1059) and with
duration.1 year (n= 781) were recruited and categorized as New-T2D and Old-T2D, respectively. Biochemical, glycemic, and
C-peptide parameters were measured.
Results: GA levels were significantly elevated in HbA1c-matched Old-T2D subjects compared to New-T2D subjects. Duration
of diabetes was positively correlated with GA, whereas a negative relationship was found with C-peptide increment (DC-
peptide). Among insulin secretory indices, dynamic parameters such as DC-peptide were inversely related to GA (r=20.42,
p,0.001). Multiple linear regression analyses showed that duration of diabetes was associated with GA (standardized b
coefficient [STDb] = 0.05, p,0.001), but not with HbA1c (STDb= 0.04, p,0.095). This association disappeared after additional
adjustment with DC-peptide (STDb= 0.02, p= 0.372), suggesting that b-cell function might be a linking factor of close
relationship between duration of diabetes and GA values.
Conclusions: The present study showed that GA levels were significantly increased in subjects with longer duration T2D and
with decreased insulin secretory function. Additional caution should be taken when interpreting GA values to assess
glycemic control status in these individuals.
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Introduction
The United Kingdom Prospective Diabetes Study (UKPDS) [1]
and Kumamoto Study [2] demonstrated that intensive glycemic
control was essential for individuals with type 2 diabetes (T2D) to
reduce risks of morbidity and mortality from diabetes-related
complications and cardiovascular diseases. In line with these
results, the purpose of glucose monitoring with glycemic indices, in
conjunction with lifestyle modification, and pharmacological anti-
diabetic drugs in diabetic subjects, is to achieve and maintain
optimal blood glucose levels [3]. Clinical data of HbA1c levels have
been shown to predict average glycemic status over several
months, and to predict diabetic complications [1,4]; therefore the
American Diabetes Association recommended routine HbA1c
testing in all diabetic patients as an initial assessment, and then as a
part of continuing care [3].
By overcoming the unmet need of well-established or gold
standard glycemic index of HbA1c [3], glycated albumin (GA)
measurements have been increasingly used as another reliable
index for 3-week intermediate glycation monitoring, and GA
measurements are further preferred for use in several pathologic
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conditions, including anemia and chronic kidney disease (CKD)
[5–7]. In addition, GA is closely associated with insulin secretory
function of b-cells [8,9]. The pathophysiologic nature of T2D is
characterized by a progressive decline in pancreatic b-cell
function, with deterioration and insulin resistance, resulting in
the failure of insulin secretion from islet cells. As duration of
diabetes increases, b-cell functions are well known to gradually
decline, which may affect the levels of GA. Considering the greater
association of GA with decreasing pancreatic b-cell functions than
with HbA1c levels in subjects with T2D, the relationship between
GA levels and diabetic duration may differ from what has been
previously accepted. However, to date there is no report on the
relationship among GA, b-cell function and duration of diabetes in
subjects with T2D. On these bases, the aim of our study was to
investigate whether GA levels are elevated in subjects with long
duration of diabetes in close connection with their insulin secretory
capacity.
Methods
Subjects and data collection
In this cross-sectional study, patients with T2D who visited the
Diabetes Center at Severance Hospital, Seoul, South Korea
between January 2009 and December 2012 were enrolled in the
Diabetes Registry of Severance Hospital, and most of the subjects
have been described in our previous studies [9–11]. The study
subjects were classified into two groups according to the duration
of diabetes. New-onset type 2 diabetes was defined as patients
whose duration of diabetes was #1 year (New-T2D), and old T2D
included patients with duration of diabetes .1 year (Old-T2D).
Based on electronic medical records, a total of 1840 subjects
satisfied the following inclusion criteria: age $18 years of age with
stably maintained HbA1c levels of ,0.5% fluctuation across 6
months of measurements and available laboratory data for HbA1c
and GA prior to a standardized liquid meal test [Ensure, Meiji
Dairies Corporation, Tokyo, Japan; 500 kcal, 17.5 g fat (31.5%),
68.5 g carbohydrate (54.5%), and 17.5 g protein (14.0%)] after an
overnight fast. Patients were excluded for the following reasons:
any medical conditions that could alter HbA1c or GA levels,
including liver cirrhosis or kidney diseases (nephrotic syndrome or
serum creatinine level $176.8 mM), pregnancy, steroid therapy,
and hematologic disorders. The protocol of this study was
approved by the Institutional Review Board at Severance Hospital
(IRB No. 4-2009-0656, 4-2012-0398, 4-2013-0103, 4-2014-0507)
and written informed consent for this study was not required by
the Institutional Review Board because researchers only accessed
the database for analysis purposes, and personal information was
not used.
Anthropometric and laboratory measurements
Using electronic medical records, demographic and clinical data
were retrospectively collected for age, gender, smoking history,
and duration of diabetes. The duration of diabetes was defined by
the date when patients were diagnosed as having diabetes by blood
tests or by patient recall from interviews. Body mass index (BMI)
was calculated as weight in kilograms divided by the square of the
height in meters. During standardized liquid meal tests, blood
samples were collected at 0 and 90 min (basal and stimulated
levels, respectively) for glucose, insulin, and C-peptide analyses.
Serum C-peptide levels were determined by an immunoradio-
metric assay method (Beckman Coulter, Fullerton, CA, USA).
Pancreatic b-cell function and insulin sensitivity were assessed
using the following indices: homeostasis model assessment of
pancreatic b-cell function (HOMA-b) = basal insulin (pM)60.48/
[basal glucose (mM)23.5], HOMA-IR= [basal insulin (pM)6glu-
cose (mM)/156.3] [12] and C-peptide increment (DC-peptide =C-
peptide, stimulated2C-peptide, basal) [13], respectively. Serum
concentrations of fasting glucose, total cholesterol, and albumin
were measured by standard methods. Serum creatinine levels were
determined with a Hitachi 7600-110 automated chemistry
analyzer (Hitachi Co., Tokyo, Japan) with CREA (Roche
Diagnostics, Indianapolis, IN, USA). Serum GA was analyzed
by an enzymatic method using an albumin-specific proteinase,
ketoamine oxidase, and an albumin assay reagent (LUCICA GA-
L; Asahi Kasei Pharma Co., Tokyo, Japan), and a Hitachi 7699 P
module autoanalyzer (Hitachi Instruments Service, Tokyo, Japan)
[14]. GA values (%) were the calculation of the ratio of GA to total
serum albumin. The coefficient of variation was 1.43%. HbA1c
was measured by high-performance liquid chromatography using
Variant II Turbo (Bio-Rad Laboratories, Hercules, CA, USA).
The reference ranges of HbA1c and GA were between 4.0% and
6.0%, and between 11.0% and 16.0%, respectively.
Statistical Analyses
All continuous variables were expressed as mean 6 standard
deviation (SD) or median (ranges) values, as appropriate. HOMA-
b, HOMA-IR, and DC-peptide were log transformed for the
analyses because the value distributions were skewed. Student’s t
test and Pearson’s x2 test were used to compare variables between
two groups, as appropriate. The differences in GA and GA/HbA1c
ratios, between two groups, were evaluated using Student’s t test
with Bonferroni correction after stratification of HbA1c levels,
because GA/HbA1c ratios are affected by HbA1c levels [10]. One-
way analysis of variance (ANOVA) was used to examine the
differences of GA/HbA1c ratios, GA, and DC-peptide levels
according to the duration of diabetes or tertiles of DC-peptide. We
analyzed the relationship between GA/HbA1c ratios and DC-
peptide, using Pearson’s correlation coefficients with scatter plots.
A spline curve was plotted for the relationship between GA and
DC-peptide levels. A multivariable linear regression model was
applied to assess various clinical and laboratory parameters
associated with HbA1c or GA. HOMA-IR was removed from
the final linear model because it had multiple collinearity with
basal insulin. Results were expressed as values of standardized b
coefficient and p. To minimize the possible effect of age on GA,
propensity-score matching was used to match ages among subjects.
A two-sided p value ,0.05 was considered significant. Statistical
analyses were carried out with SPSS version 20.0 for Windows
(IBM Corp., Armonk, NY, USA) and SAS version 9.2 (SAS
Institute).
Results
Study population characteristics
New-T2D of 1059 subjects, defined as #1 year of diabetes
duration, and 781 subjects with Old-T2D defined as .1 year of
diabetes duration, were included in the present study. The patient
characteristics of the cohort are shown in Table 1. Median
durations of diabetes were 0.5 year and 4.4 years in New-T2D and
Old-T2D, respectively. Individuals in the New-T2D group were
younger and had lower levels of glucose at 90 min, while they had
significantly higher values of stimulated C-peptide, DC-peptide,
and total cholesterol. While HbA1c levels were similar in the two
groups (7.861.9 vs. 7.961.6, p=0.159, respectively), both GA
(19.667.8 vs. 20.967.4, p,0.001, respectively) and GA/HbA1c
ratios (2.4760.50 vs. 2.6160.53, p,0.001, respectively) were
significantly increased in Old-T2D subjects, when compared to
the New-T2D subjects.
Association between Glycated Albumin and Diabetes Duration
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Glycated albumin levels were elevated in subjects with
long duration of diabetes
Based on recent studies, the levels of GA and GA/HbA1c ratios
were higher in subjects with poorly controlled diabetes than in
subjects with well-controlled diabetes, whereas HbA1c levels were
not different [10]. Likewise, patients with longer diabetes duration
tend to have higher HbA1c levels [15]. Therefore, GA and GA/
HbA1c ratios in this study were compared, according to HbA1c
strata (Fig. 1). In the ranges of HbA1c levels ,8%, and 8 to 10%,
both GA and GA/HbA1c ratios in Old-T2D were significantly
higher than in New-T2D. Average GA values in Old-T2D subjects
were 0.9 to 1.6% higher than in New-T2D subjects.
To assess the association between GA-related indices and
diabetes duration, the duration of diabetes was categorized into
quartiles. Consistent with the results shown in Fig. 1, GA (Fig. 2A)
and GA/HbA1c ratios (Fig. S1) were significantly and sequentially
increased across the quartiles of diabetes duration. However, as
diabetes duration increased, the level of DC-peptide, an insulin
secretory index of b-cells, was statistically decreased (Fig. 2B),
indicating the gradual deterioration of reserve b-cell function over
time.
Glycated albumin was negatively correlated with insulin
secretory indices
Considering the detrimental effects of diabetes duration on GA/
HbA1c ratio and DC-peptide levels, correlation analysis was
performed to assess the link between GA-related indices and
parameters of b-cell functions (Table 2 and Fig. 3). Simple and
partial correlation analyses both showed that GA levels were
negatively related to insulin secretory indices such as HOMA-b,
Dinsulin, and basal C-peptide, whereas basal insulin levels had no
significant correlation with GA (Table 2 and Fig. S2). Duration of
diabetes was also positively related to GA levels (r=0.12, p,
0.001), regardless of age. Strong inverse correlation was found
between DC-peptide levels and GA (r=20.41, p,0.001 in
Table 2, or Fig. 3A) or GA/HbA1c ratios (r=20.35, p,0.001,
Fig. S3), regardless of age and gender. Values of both GA (Fig. 3B)
and GA/HbA1c ratios (Fig. S3) were gradually decreased as
quartiles of DC-peptide levels increased.
Table 1. Baseline characteristics of the study population.
New T2D Old T2D P
diabetes duration #1 y (N=1059) diabetes duration .1 y (N=781)
Age (years) 56.8612.3 60.7611.3 ,0.001
Sex (M/F, %Female) 625/434 (41) 435/346 (44) 0.154
Duration of diabetes (years) 0.5 (0–0.99) 4.4 (1.00–43.44) ,0.001
BMI (kg/m2) 25.363.6 25.163.7 0.486
Smoking (never/past/current) 645/224/190 502/139/140 0.184
Glycemic profiles
Glucose, basal (mM) 7.662.7 7.562.5 0.768
Glucose, stimulated (mM) 12.264.9 12.864.4 0.005
HbA1c (%) 7.861.9 7.961.6 0.159
HbA1c (mM/M) 61.6620.3 62.8617.0 0.159
Glycated albumin (%) 19.667.8 20.967.4 ,0.001
GA/HbA1c ratio 2.4760.50 2.6160.53 ,0.001
C-peptide, basal (nM) 0.8260.45 .7960.43 0.188
C-peptide, stimulated (nM) 2.1061.03 1.9060.94 ,0.001
DC-peptide (nM)* 1.2960.87 1.1160.76 ,0.001
Insulin, basal (pM) 82.8691.1 83.5697.2 0.903
Insulin, stimulated (pM) 400.16355.2 348.66280.6 0.003
HOMA-IR* 3.564.4 3.965.1 0.097
HOMA-b* 85.46188.2 82.66160.7 0.776
Biochemistry profiles
Total cholesterol (mM) 4.761.2 4.361.0 ,0.001
HDL cholesterol (mM) 1.260.3 1.260.3 0.660
LDL cholesterol (mM) 2.861.0 2.460.8 ,0.001
Albumin (g/L) 45.063.7 45.163.4 0.763
Creatinine (mM) 81.8620.5 86.0623.1 ,0.001
*log transformed.
Variables were described as mean 6 SD or median (ranges).
BMI, body mass index; HOMA-IR, homeostasis model assessment of insulin resistance; HOMA-b, homeostasis model assessment of pancreatic b-cell function.
doi:10.1371/journal.pone.0108772.t001
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The association between glycated albumin and C-
peptide increment (DC-peptide) accounted for increased
levels of glycated albumin in subjects with longer
duration of diabetes
Multiple linear regression models were applied to determine the
clinical and laboratory parameters associated with HbA1c or GA
(Table 3). In model 1, which included clinically and statistically
important variables except DC-peptide levels, duration of diabetes
had a positive correlation with both GA (standardized [STD]
b=0.05, p=0.02) and GA/HbA1c ratio (STD b=0.05, p=0.03,
Table S1), but not with HbA1c levels (STD b=0.04, p=0.10).
Contrary to glucose profiles, both age and serum albumin levels
were negatively correlated with HbA1c levels, while BMI, total
cholesterol, and albumin levels were negatively correlated with GA
(model 1). After additional adjustment for DC-peptide levels in the
existing model (model 2), the significant correlation of duration of
diabetes with GA (STD b=0.02, p=0.37) or with GA/HbA1c
Figure 1. Differences of glycated albumin (GA) and GA/HbA1c ratios according to the duration of diabetes by HbA1c ranges. (A)
glycated albumin; (B) GA/HbA1c ratio. Data are shown as mean with SD (bars). *P,0.001 compared to those from subjects with New-T2D.
doi:10.1371/journal.pone.0108772.g001
Figure 2. Association between duration of diabetes and glycated albumin or C-peptide increment (DC-peptide). (A) Difference of
glycated albumin levelsaccording to the duration of diabetes; (B) Difference of DC-peptide levels according to the duration of diabetes. Data are
shown as mean with SD (bars).
doi:10.1371/journal.pone.0108772.g002
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ratio (STD b=0.02, p=0.43, Table S1) disappeared. However,
DC-peptide level was strongly associated with both GA and GA/
HbA1c ratio (STD b=20.22 and 20.21, respectively; both p,
0.001), which led to increments of R2 values (from 0.36 in Model 1
to 0.40 in Model 2). These findings remained consistent in further
analysis with age-matched study population (Table S2).
Discussion
The present study observed that GA levels or GA/HbA1c ratios
were elevated in Old-T2D subjects than in New-T2D subjects,
regardless of their glycemic control status (HbA1c levels). With
respect to insulin-related parameters, GA was negatively correlat-
ed with dynamic insulin secretory indices, but not with basal
insulin levels. In addition, GA, but not HbA1c was significantly
associated with duration of diabetes. This association did not
remain after additional adjustment with DC-peptide in the
regression model, indicating that insulin secretory function played
a major role in this close relationship between GA and duration of
diabetes. Although this is a cross-sectional study which cannot
draw any causal relationships, we may suggest that GA values are
Figure 3. Association between glycated albumin and C-peptide increment (DC-peptide). (A) A plot of spline curve for association
between glycated albumin and DC-peptide levels. Data plotted by a spline curve (dark blue) and 95% confidence interval (light blue); (B) Difference
of glycated albumin levels according to the DC-peptide levels.
doi:10.1371/journal.pone.0108772.g003
Table 2. Correlation analyses to determine the association between glycated albumin and other variables including insulin
secretory indices and the duration of diabetes.
Glycated albumin
Simple correlation Partial correlation*
r P r P
Age (years) 20.010 0.680 – –
BMI (kg/m2) 20.185 ,0.001 20.200 ,0.001
Glucose, basal (mM) 0.614 ,0.001 0.670 ,0.001
Glucose, stimulated (mM) 0.676 ,0.001 0.704 ,0.001
Total cholesterol (mM) 0.033 0.181 0.005 0.878
HOMA-IR 0.186 ,0.001 0.201 ,0.001
HOMA-b 20.072 0.006 20.120 ,0.001
Insulin, basal (pM) 0.026 0.314 0.029 0.355
DInsulin (pM) 20.295 ,0.001 20.318 ,0.001
C-peptide, basal (nM) 20.148 ,0.001 20.128 ,0.001
DC-peptide (nM) 20.412 ,0.001 20.442 ,0.001
Albumin (g/L) 20.091 ,0.001 20.108 ,0.001
Creatinine (mM) 0.026 0.306 20.005 0.882
Duration of diabetes (years) 0.123 ,0.001 0.120 ,0.001
Partial correlation* was conducted with adjustment for age and sex.
doi:10.1371/journal.pone.0108772.t002
Association between Glycated Albumin and Diabetes Duration
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indirectly associated with the long duration of T2D, because b-cell
function gradually decreases as duration of diabetes increases
(Fig. 4). Impaired insulin secretion from b-cells can increase blood
glucose excursions, which is more sensitively reflected by GA
compared to HbA1c.
HbA1c levels depend on glucose transport from plasma into
erythrocytes and on intracellular glucose and protein metabolism,
which indirectly reflect glycemic status. However, GA is not
affected by extracellular–intracellular glucose dynamics [16], but
directly produced by the glycation process in the plasma. In
addition, GA level is not changed by serum concentration of
albumin, because it is calculated by the glycated proportion of
total serum albumin [17]. However, several factors can influence
GA values. It is well known that obesity (BMI) is inversely
associated with GA [18], which is consistent with our regression
analyses. This result may be due to increased albumin catabolism
induced by chronic micro-inflammatory conditions in obese
subjects [19]. Likewise, GA levels are more inaccurate compared
to HbA1c values in certain diseases affecting albumin metabolism
[17]. During hyper-metabolic states of albumin, such as nephrotic
syndrome, hyperthyroidism, and glucocorticoid treatment, GA
increases in relation to blood glucose, while it decreases in subjects
with diminished albumin catabolism, including liver cirrhosis and
hypothyroidism [17]. To minimize the effects of erythrocytes or
albumin turnover on HbA1c or GA values, we excluded subjects
who had liver cirrhosis or CKD, pregnancy, steroid therapy, and
hematologic disorders such as anemia.
In addition to the above listed pathologic conditions, the present
study showed that GA or GA/HbA1c ratios were significantly
increased in subjects with longer duration of T2D. Duration of
diabetes was indirectly associated with GA and decreased b-cell
function might be the linking factor between duration of diabetes
and GA values. This was supported by our results from linear
regression analyses showing that diabetic duration was associated
with GA, of which association disappeared after adjustment with
b-cell function index (DC-peptide). Among various insulin
secretory indices, static parameters such as basal insulin or
HOMA-b showed no or minimal relationships with GA, whereas
dynamic parameters such as DC-peptide or Dinsulin had strong
correlation with GA. To date, it is still not known why GA is
closely correlated with endogenous insulin secretory function. GA
is known to function as a pathogenic protein as well as an index for
glycemic status, because it is an early precursor of advanced
glycation end-products (AGE), which cause alterations in various
cellular proteins and organelles, leading to apoptosis [5]. A recent
report suggested that GA induced pancreatic b-cell dysfunction
and death by disrupting cellular defense homeostasis [20].
Similarly, GA directly suppressed glucose-stimulated insulin
secretion from rat pancreatic b-cells through impairment of
intracellular glucose metabolism [21]. These may support the
inverse relationship found between GA and b-cell function,
because increased circulating levels of GA can lead to secretory
dysfunction in b-cells, a pathophysiology known as glucolipotoxi-
city. In addition, considering the role of GA as a short-term (3-
week) glycemic index, GA may reflect glucose fluctuation and
postprandial glucose more sensitively than HbA1c [10,22–24].
Our study has some distinct strengths. This was a rather large
population-based study consisting of both newly diagnosed and
long duration of T2D subjects, which could detect mild association
of diabetes duration with GA and enhance the statistical reliability
of the results. Our findings that GA is significantly elevated relative
to HbA1c in certain patients with T2D, may raise serious issues
regarding GA as an adequate index for monitoring glycemic
control, especially in subjects with longer duration of diabetes, or
severely impaired endogenous insulin secretion, such as during
type 1 diabetes. Consistent with our results, Koga et al. reported
that GA/HbA1c ratios were elevated in T2D patients treated with
insulin, as well as in autoimmune acute-onset type 1 diabetic
patients [8,25]. This was attributed to strong links between GA
and b-cell function. Because GA is less consistent in predicting
blood glucose levels among subjects who have newly-diagnosed or
long-standing T2D compared to HbA1c, clinicians should be
cautious when using GA as a substitute index for monitoring
glycemic status, especially in terms of long-term follow-up.
Although GA is a superior index to HbA1c for subjects with
anemia or CKD, duration of diabetes as well as insulin secretory
function should be taken into consideration when interpreting GA
values.
The current study has several potential limitations, which
should be addressed by future research. First, the cross-sectional
approach did not allow us to draw complete conclusions regarding
time-dependent changes of GA and GA/HbA1c ratios in subjects
with T2D or with transition in b-cell function. Second, assessment
of endogenous insulin secretory function was confined to C-
peptide-related indices. Due to lack of data from oral glucose
tolerance tests, various insulin secretory parameters were not
analyzed in this study. Third, other factors such as anti-diabetic
medication, which may affect the variation in GA levels, were not
evaluated. Lastly, duration of diabetes was unable to be assessed
precisely in each individual due to slow-progressive characteristics
of T2D, but was clinically defined, similar to previous studies [26].
Therefore, its pathognomic meaning is feeble.
Figure 4. A putative diagram of the relationship among glycated albumin, b-cell function and duration of diabetes.
doi:10.1371/journal.pone.0108772.g004
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In conclusion, the present study clearly showed that GA/HbA1c
ratios were significantly elevated in subjects with longer duration
of T2D, largely due to inverse relationships between GA and b-cell
secretory indices. Clinicians should be careful in interpreting GA
values as assessment indices of glycemic control in these
individuals. Future investigation is warranted to elucidate the
mechanism of the negative association between GA and b-cell
function, and to validate the role of GA as a reliable index for
long-term glycemic monitoring in various clinical conditions.
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